Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAXNASDAQ:COGTNASDAQ:LYELNASDAQ:OPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$9.57+1.1%$12.71$7.80▼$28.09$522.13MN/A541,833 shs373,132 shsCOGTCogent Biosciences$5.28+8.1%$5.04$3.72▼$12.61$599.45M1.911.26 million shs1.29 million shsLYELLyell Immunopharma$0.41$0.45$0.39▼$2.80$121.38M-0.251.03 million shs119,716 shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.1226,802 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics-5.21%-35.16%-36.12%-23.46%+945,999,900.00%COGTCogent Biosciences0.00%-2.01%-0.61%-30.19%-41.97%LYELLyell Immunopharma-0.15%0.00%-7.03%-42.48%-85.09%OPTOpthea0.00%0.00%0.00%-25.87%+8.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara Therapeutics1.8004 of 5 stars3.50.00.00.02.00.80.6COGTCogent Biosciences1.4779 of 5 stars3.40.00.00.03.40.00.6LYELLyell Immunopharma2.2598 of 5 stars2.80.00.00.02.15.01.3OPTOpthea0.9276 of 5 stars2.10.00.00.02.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$31.86233.07% UpsideCOGTCogent Biosciences 2.75Moderate Buy$14.57176.24% UpsideLYELLyell Immunopharma 1.50Reduce$1.00143.90% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideCurrent Analyst Ratings BreakdownLatest LYEL, OPT, COGT, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $25.005/23/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$8.005/23/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.005/20/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/16/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $41.005/7/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.004/17/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight$8.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/7/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $44.003/27/2025BCAXBicara TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$48.003/27/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/ALYELLyell Immunopharma$65K1,862.90N/AN/A$2.60 per share0.16OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/A6/26/2025 (Estimated)COGTCogent Biosciences-$192.41M-$1.84N/AN/AN/AN/A-112.55%-60.44%8/5/2025 (Estimated)LYELLyell Immunopharma-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/ALatest LYEL, OPT, COGT, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BCAXBicara Therapeutics-$0.40-$0.68-$0.28-$0.68N/AN/A5/13/2025Q1 2025LYELLyell Immunopharma-$0.19-$0.18+$0.01-$0.18N/A$0.01 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/A3/27/2025Q4 2024BCAXBicara Therapeutics-$0.31-$0.39-$0.08-$0.39N/AN/A3/12/2025Q4 2024LYELLyell Immunopharma-$0.20-$0.72-$0.52-$0.72N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/AN/AN/ACOGTCogent BiosciencesN/A6.446.44LYELLyell ImmunopharmaN/A13.4313.43OPTOptheaN/A2.942.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ACOGTCogent BiosciencesN/ALYELLyell Immunopharma66.05%OPTOpthea55.95%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics15.50%COGTCogent Biosciences5.92%LYELLyell Immunopharma25.10%OPTOpthea3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.54 millionN/AN/ACOGTCogent Biosciences80113.86 million103.92 millionOptionableLYELLyell Immunopharma270295.34 million218.83 millionOptionableOPTOpthea8153.91 million148.98 millionNot OptionableLYEL, OPT, COGT, and BCAX HeadlinesRecent News About These CompaniesOpthea Limited (NASDAQ:OPT) Given Average Rating of "Hold" by AnalystsMay 17, 2025 | marketbeat.comHsbc Holdings PLC Makes New Investment in Opthea Limited (NASDAQ:OPT)May 9, 2025 | marketbeat.comBiotech Dimerix lands $940m licensing deal for kidney drug salesMay 1, 2025 | afr.comPhil King’s Regal successfully bets against Tesla, NvidiaMay 1, 2025 | afr.com'No one is happy': Regal stockpickers face financial hit after Opthea blow upApril 21, 2025 | capitalbrief.comRegal’s King says his hedge funds will recover from March madnessApril 16, 2025 | afr.comRegal: Don’t catch the falling knife, wait for it to stick in the floorApril 16, 2025 | msn.comOpthea to lay off approximately 65% of companyApril 10, 2025 | ophthalmologytimes.comOpthea lays off 65% of staff after back-to-back phase 3 eye disease flopsApril 10, 2025 | fiercebiotech.comBELL POTTER SECURITIES Downgrades Opthea (CKDXF)April 9, 2025 | msn.comBELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)April 9, 2025 | msn.comASX drops as US jumbo China tariff takes effectApril 9, 2025 | afr.comOpthea Limited (CKDXF) was downgraded to a Sell Rating at Bell PotterApril 3, 2025 | markets.businessinsider.comPhil King’s Regal writes Opthea to zero and backs off risky betsApril 2, 2025 | afr.comOpthea Ends Development of Sozinibercept in Wet AMDMarch 31, 2025 | marketwatch.comLifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drugMarch 31, 2025 | endpts.comOpthea terminates COAST trial, announces ShORe trial misses endpointMarch 31, 2025 | markets.businessinsider.comOpthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 failMarch 31, 2025 | fiercebiotech.comOpthea discontinues development of sozinibercept in wet AMDMarch 31, 2025 | healio.comOpthea Announces Decision to Discontinue Wet AMD TrialsMarch 31, 2025 | globenewswire.comOpthea Limited’s Securities Suspended Due to Financial ConcernsMarch 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Here's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock LYEL, OPT, COGT, and BCAX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$9.56 +0.11 (+1.11%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Cogent Biosciences NASDAQ:COGT$5.28 +0.40 (+8.09%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Lyell Immunopharma NASDAQ:LYEL$0.41 0.00 (0.00%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 05/28/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
